It very well may have some correlation... Genzyme is telling Sanofi-Aventis pay full price if you want us $80 billion! Pretty big statement. Genetic-disease drugmaker Genzyme Corp must have something Sanofi needs and maybe it doesn't have anymore time to develop something similar.
That's what makes CBAI special in todays market. Aside from whatever back room dealings it has space. Fill capacity 250k and has passed the FDA regulatory scrutiny and is accredited.
How long would it take a competitor to buildout 17,000 sf worth of storage space? Time is money. Thoughts?
News 
Market Data 
Discover 
